VENLO, Netherlands, June 18, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on ...

Life sciences firm Qiagen said on Monday it has acquired DNA-biometrics firm Verogen in a $150-million cash deal, strengthening its forensics portfolio. Skip to main content.

Qiagen NV, a Dutch maker of genetic-testing equipment, said it will acquire Digene Corp. in a cash-and-stock deal valued at $1.6 billion, in a move to expand into testing for cervical cancer and ...

Diagnostics company Qiagen said on Monday it was targeting 7% currency-adjusted sales growth per year until 2028 on lab testing machines for infections and cancer, as it maps out its post-pandemic ...

Recently, QIAGEN announced it has entered into talks to purchase a 47 percent initial stake in France's Ipsogen and subsequently make a public offer to fully acquire the company. The potential ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has signed agreements to acquire a 96% majority ownership stake in BLI ...

Qiagen typically operates with an easy-to-manage balance sheet. As of March 2024, the company owed $1.5 billion of debt and held $0.9 billion of cash and investments on its balance sheet ...

QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics ...